Collegium Pharmaceutical, Inc. last reported quarterly results on Nov 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $216.3 million (+3.3% year over year) and diluted EPS of $0.60. It usually reports 36–57 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 25, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Feb 26, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 36–57 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 5, 2026
36 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
216
+3.3%
|
22
-30.9%
|
0.60
-28.6%
|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
200
+6.3%
|
-15
-225.6%
|
-0.46
-235.3%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
194
+8.9%
|
14
+499.8%
|
0.40
+471.4%
|
|
Feb 26, 2026
57 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
205
+12.9%
|
17
+35.3%
|
0.46
+27.8%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
209
+31.4%
|
32
+237.5%
|
0.84
+211.1%
|
|
Aug 7, 2025
38 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
188
+29.4%
|
12
-38.9%
|
0.34
-34.6%
|
|
May 8, 2025
38 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
178
+22.7%
|
2
-91.3%
|
0.07
-90.1%
|
|
Feb 27, 2025
58 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
182
+21.5%
|
13
-60.8%
|
0.36
-56.1%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- COLL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- VA
- Headquarters
- Stoughton, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1267565
- Former names
- COLLEGIUM PHARMACEUTICAL INC (until Mar 3, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.